eisai enters into license agreement for fosravuconazole in asia/oceania with sato pharma – eisai china lnc.-爱游戏app官网入口

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that the company has
entered into a license agreement regarding the development and commercialization rights for the
antifungal agent fosravuconazole in the asia/oceania region* with sato pharmaceutical co., ltd.
(headquarters: tokyo, “sato pharma”). under this agreement, eisai exclusively licenses the intellectual
property rights of fosravuconazole in the given countries/regions to sato pharma.

ravuconazole, the active ingredient of fosravuconazole, is an antifungal agent discovered and developed
by eisai. fosravuconazole is a prodrug of ravuconazole, which improves its solubility and bioavailability.
in japan, seren pharma (headquarters: tokyo) and sato pharma have developed fosravuconazole based
on the exclusive rights to develop, commercialize, and sublicense granted by eisai. the treatment has
been marketed by sato pharma as the oral antifungal agent nailin® for the indication of “onychomycosis”
since july 2018, which eisai is co-promoting.

under the terms of the agreement, eisai will receive a contractual upfront payment, and the rights to receive
regulatory milestone payments and royalties based on sales over a certain period. eisai will retain
development and commercialization rights related to mycetoma, a neglected tropical disease, and its
associated conditions, as these are excluded from the licensing.

upon the conclusion of this agreement, eisai hopes to maximize the value of fosravuconazole in the
asia/oceania region, ensuring the earliest possible contribution to patients in need of the medicine.

*10 asean nations, australia, new zealand, south korea, and taiwan